Neuberger Berman Group
BIO icon

Neuberger Berman Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Neuberger Berman Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.8M Buy
111,812
+108,783
+3,591% +$30.9M 0.02% 597
2026
Q1 		$844K Buy
3,029
+19
+0.6% +$5.47K ﹤0.01% 1472
2025
Q4 		$912K Buy
3,010
+193
+7% +$60.2K ﹤0.01% 1432
2025
Q3 		$790K Buy
2,817
+1,201
+74% +$327K ﹤0.01% 1441
2025
Q2 		$390K Sell
1,616
-31
-2% -$7.33K ﹤0.01% 1658
2025
Q1 		$401K Sell
1,647
-1,252
-43% -$377K ﹤0.01% 1600
2024
Q4 		$952K Buy
2,899
+6
+0.2% +$2.04K ﹤0.01% 1325
2024
Q3 		$968K Buy
2,893
+1,017
+54% +$323K ﹤0.01% 1310
2024
Q2 		$512K Sell
1,876
-44
-2% -$12.8K ﹤0.01% 1487
2024
Q1 		$664K Sell
1,920
-1,768
-48% -$581K ﹤0.01% 1400
2023
Q4 		$1.19M Sell
3,688
-54,877
-94% -$17.2M ﹤0.01% 1439
2023
Q3 		$21M Buy
58,565
+662
+1% +$255K 0.02% 594
2023
Q2 		$22M Buy
57,903
+147
+0.3% +$59.8K 0.02% 594
2023
Q1 		$27.7M Buy
57,756
+20
+0% +$9.36K 0.03% 550
2022
Q4 		$24.3M Buy
57,736
+401
+0.7% +$162K 0.02% 573
2022
Q3 		$23.9M Sell
57,335
-433
-0.7% -$216K 0.03% 574
2022
Q2 		$28.6M Buy
57,768
+3,075
+6% +$1.6M 0.03% 545
2022
Q1 		$30.8M Buy
54,693
+58
+0.1% +$35K 0.03% 578
2021
Q4 		$41.1M Buy
54,635
+595
+1% +$445K 0.03% 523
2021
Q3 		$40.2M Sell
54,040
-24,713
-31% -$18.5M 0.04% 518
2021
Q2 		$50.6M Buy
78,753
+14,834
+23% +$9.03M 0.04% 462
2021
Q1 		$36.5M Buy
63,919
+10,698
+20% +$6.34M 0.03% 523
2020
Q4 		$31M Sell
53,221
-11,206
-17% -$6.38M 0.03% 531
2020
Q3 		$33.2M Buy
64,427
+33
+0.1% +$16.7K 0.04% 454
2020
Q2 		$29.1M Buy
64,394
+153
+0.2% +$67.5K 0.04% 479
2020
Q1 		$22.5M Sell
64,241
-29,992
-32% -$11M 0.03% 488
2019
Q4 		$34.9M Sell
94,233
-20,459
-18% -$7.21M 0.04% 473
2019
Q3 		$38.2M Buy
114,692
+5
+0% +$1.63K 0.05% 437
2019
Q2 		$35.9M Sell
114,687
-24
-0% -$7.19K 0.04% 462
2019
Q1 		$35.1M Buy
114,711
+201
+0.2% +$54.2K 0.04% 467
2018
Q4 		$26.6M Sell
114,510
-873
-0.8% -$234K 0.04% 491
2018
Q3 		$36.1M Sell
115,383
-1,117
-1% -$347K 0.04% 485
2018
Q2 		$33.6M Sell
116,500
-13,500
-10% -$3.73M 0.04% 504
2018
Q1 		$32.5M Sell
130,000
-1,273
-1% -$324K 0.04% 509
2017
Q4 		$31.3M Sell
131,273
-120
-0.1% -$29.1K 0.04% 530
2017
Q3 		$29.2M Buy
131,393
+22,050
+20% +$4.96M 0.04% 524
2017
Q2 		$24.7M Buy
109,343
+23,116
+27% +$5.04M 0.03% 558
2017
Q1 		$17.2M Buy
86,227
+33,264
+63% +$6.41M 0.02% 635
2016
Q4 		$9.65M Buy
+52,963
New +$9.03M 0.01% 751

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Neuberger Berman Group's BIO Position: Q2 2026 in Review

Neuberger Berman Group increased its Bio-Rad Laboratories Class A (BIO) stake by 3,591% in Q2 2026, buying an estimated $30.9M and bringing the position to 111,812 shares worth $32.8M. The position accounts for 0.02% of the portfolio, ranked #597.

Neuberger Berman Group first reported a position in BIO in Q4 2016 and has held it in 39 quarters since. The position peaked at $50.6M in Q2 2021. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Neuberger Berman Group held 111,812 shares of Bio-Rad Laboratories Class A worth $32.8M as of Q2 2026.
  • Neuberger Berman Group bought 108,783 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $30.9M.
  • Bio-Rad Laboratories Class A made up 0.02% of Neuberger Berman Group's portfolio in Q2 2026, its #597 holding.
  • Neuberger Berman Group first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and has held it in 39 quarters since.
  • Neuberger Berman Group's Bio-Rad Laboratories Class A position peaked at $50.6M in Q2 2021.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.